TLR3 and neoplasm: TLR3 ligand poly A:U shifts the immunosuppressive tumor microenvironment towards anti-tumor immunity by altering the composition in favor of antigen-specific CD8+ granzyme B+ T cells, resulting in a lower Treg/CD8+ cell ratio (127).